Recent Updates
Recently added Catalysts

losartan hydrochlorothiazide

Phase 3

Hypertension | Small molecule | Cardiovascular |Merck & Company, Inc.|Last Updated: May 9, 2017

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

UNCONTROLLED
Total Trials1
Total Enrollment437

FDA Designations

No designations recorded

Clinical trial landscape

losartan hydrochlorothiazide · 1 trial · 1 indication

Phase 3 1
NCT00354991Hyzaar Asia HEAALTH (0954A-950)Hypertension
COMPLETED437 Analytics
PHASE3COMPLETED
Hyzaar Asia HEAALTH (0954A-950)
HypertensionUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of patients reaching a blood pressure goal (diastolic <90mm Hg for non-diabetics; <80mm Hg for diabetics) after 8 weeks of treatment
8 Weeks

Secondary Endpoints

Safety and tolerability
13 Weeks
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
1EXPERIMENTALLosartan/HCTZ

Interventions

NameTypeDescription
losartan potassium (+) hydrochlorothiazideDRUGPatients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo

Inclusion Criteria: * Patient is male or female and = 18 years of age * Patients with essential hypertension previously treated with antihypertensive medications for at least 4 weeks but did not reach the blood pressure goal Exclusion Criteria: * History of any condition, therapy, lab abnormality...

Unlock Eligibility Criteria